<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">13828</article-id><article-id pub-id-type="doi">10.7554/eLife.13828</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group></article-categories><title-group><article-title>Blockade of glucagon signaling prevents or reverses diabetes onset only if residual β-cells persist</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-49145"><name><surname>Damond</surname><given-names>Nicolas</given-names></name><aff><institution content-type="dept">Department of Genetic Medicine, Development of the Faculty of Medicine, Institute of Genetics and Genomics in Geneva, Centre facultaire du diabète</institution>, <institution>University of Geneva</institution>, <addr-line><named-content content-type="city">Geneva</named-content></addr-line>, <country>Switzerland</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-49146"><name><surname>Thorel</surname><given-names>Fabrizio</given-names></name><aff><institution content-type="dept">Department of Genetic Medicine, Development of the Faculty of Medicine, Institute of Genetics and Genomics in Geneva, Centre facultaire du diabète</institution>, <institution>University of Geneva</institution>, <addr-line><named-content content-type="city">Geneva</named-content></addr-line>, <country>Switzerland</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-49156"><name><surname>Moyers</surname><given-names>Julie S</given-names></name><aff><institution content-type="dept">Lilly Research Laboratories</institution>, <institution>Eli Lilly and Company</institution>, <addr-line><named-content content-type="city">Indianapolis</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-49157"><name><surname>Charron</surname><given-names>Maureen J</given-names></name><aff><institution content-type="dept">Departments of Biochemistry, Medicine, and Obstetrics &amp; Gynecology and Women's Health</institution>, <institution>Albert Einstein College of Medicine</institution>, <addr-line><named-content content-type="city">Bronx</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-49158"><name><surname>Vuguin</surname><given-names>Patricia M</given-names></name><aff><institution content-type="dept">Pediatric Endocrinology, Women's and Childrens Health, College of Physicians &amp; Surgeons</institution>, <institution>Columbia University</institution>, <addr-line><named-content content-type="city">New York</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-49159"><name><surname>Powers</surname><given-names>Alvin C</given-names></name><aff><institution content-type="dept">Division of Diabetes, Endocrinology &amp; Metabolism, Department of Medicine, Department of Molecular Physiology</institution>, <institution>Vanderbilt University</institution>, <addr-line><named-content content-type="city">Nashville</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-45911"><name><surname>Herrera</surname><given-names>Pedro L</given-names></name><aff><institution content-type="dept">Department of Genetic Medicine, Development of the Faculty of Medicine, Institute of Genetics and Genomics in Geneva, Centre facultaire du diabète</institution>, <institution>University of Geneva</institution>, <addr-line><named-content content-type="city">Geneva</named-content></addr-line>, <country>Switzerland</country><email>Pedro.Herrera@unige.ch</email></aff><xref ref-type="fn" rid="conf1"/></contrib></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-36173"><name><surname>Rutter</surname><given-names>Guy</given-names></name><role>Reviewing editor</role><aff><institution> </institution>, <country>United Kingdom</country></aff></contrib></contrib-group><pub-date date-type="pub" publication-format="electronic"><day>19</day><month>04</month><year>2016</year></pub-date><elocation-id>e13828</elocation-id><supplementary-material><ext-link xlink:href="elife-13828-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material><history><date date-type="received"><day>18</day><month>12</month><year>2015</year></date><date date-type="accepted"><day>07</day><month>04</month><year>2016</year></date></history><permissions><copyright-statement>© 2016, Damond et al</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Damond et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><abstract><p>Glucagon secretion dysregulation in diabetes fosters hyperglycemia. Recent studies report that mice lacking glucagon receptor (<italic>Gcgr<sup>-/-</sup></italic>) do not develop diabetes following streptozotocin (STZ)-mediated ablation of insulin-producing β-cells. Here, we show that diabetes prevention in STZ-treated <italic>Gcgr<sup>-/-</sup></italic> animals requires remnant insulin action originating from spared residual β-cells: these mice indeed became hyperglycemic after insulin receptor blockade. Accordingly, <italic>Gcgr<sup>-/-</sup></italic> mice developed hyperglycemia after induction of a more complete, diphtheria toxin (DT)-induced β-cell loss, a situation of near-absolute insulin deficiency similar to type 1 diabetes. In addition, glucagon deficiency did not impair the natural capacity of ncy did not impair the natural capacity α-cells to reprogram into insulin production after extreme β-cell loss. α-to-β-cell conversion was improved in <italic>Gcgr<sup>-/-</sup></italic> mice as a consequence of α-cell hyperplasia. Collectively, these results indicate that glucagon antagonism could i) be a useful adjuvant therapy in diabetes only when residual insulin action persists, and ii) help devising future β-cell regeneration therapies relying upon α-cell reprogramming.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group></article-meta></front><back><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Julie S Moyers, J.S.M. is an employee and shareholder of Eli Lilly and Company.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All mice were housed and treated in accordance with the guidelines and regulations of the Direction Générale de la Santé, state of Geneva (license number GE/103/14).</p></fn></fn-group></back></article>